Voloridge Investment Management LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Voloridge Investment Management LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 212,128 shares of the biopharmaceutical company’s stock, valued at approximately $151,105,000. Regeneron Pharmaceuticals makes up about 0.5% of Voloridge Investment Management LLC’s portfolio, making the stock its 26th largest holding.

Other institutional investors have also modified their holdings of the company. Rakuten Securities Inc. lifted its position in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 15 shares during the last quarter. OFI Invest Asset Management purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $28,000. Avalon Trust Co purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $36,000. Crowley Wealth Management Inc. purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $36,000. Finally, Private Wealth Management Group LLC lifted its position in Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 39 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.4%

Shares of REGN opened at $596.54 on Tuesday. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm’s 50-day moving average is $598.10 and its two-hundred day moving average is $680.17. Regeneron Pharmaceuticals, Inc. has a twelve month low of $520.50 and a twelve month high of $1,211.20. The firm has a market capitalization of $64.41 billion, a P/E ratio of 15.58, a PEG ratio of 2.34 and a beta of 0.43.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. During the same quarter in the previous year, the company posted $9.55 earnings per share. The company’s quarterly revenue was down 3.7% compared to the same quarter last year. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.59%. Regeneron Pharmaceuticals’s payout ratio is currently 8.96%.

Analyst Ratings Changes

REGN has been the subject of a number of research reports. StockNews.com cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, May 1st. Wells Fargo & Company reduced their price target on shares of Regeneron Pharmaceuticals from $750.00 to $700.00 and set an “overweight” rating for the company in a research report on Wednesday, April 30th. Bank of America dropped their price objective on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating on the stock in a research note on Thursday, April 17th. Robert W. Baird dropped their price objective on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating on the stock in a research note on Friday, April 25th. Finally, Truist Financial dropped their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating on the stock in a research note on Wednesday, April 30th. One analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have issued a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $890.60.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.